OGN vs RTX · P/E 3.4, rev $6.40B vs P/E 36, rev $88.60B
Organon & Co (OGN) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported RTX revenue for 2025-12-31 was $88.60B. Net income was $6.73B. Revenue was up 9.7% from 2024-12-31 to 2025-12-31. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the OGN and RTX stock pages for the full models.
Not investment advice.